Retinal Vein Occlusion (RVO) occurs when the vein draining blood from the retina is blocked, leading to complications such as macular edema and vision loss.

Researchers have found that psoriasis significantly increases the risk of retinal vein occlusion (RVO) in patients with Type ...

Roche, represented by Ali Abdulwahab Al Mutawa Commercial Company (AAW) in Kuwait, announced today that the European ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

Paracentral scotomas and specific patterns of central vision loss in patients with suspected central retinal vein occlusions (CRVO) should raise suspicion for concurrent paracentral acute middle ...

There is a simple discount patient access scheme for faricimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

NICE has recommended faricimab within its anticipated marketing authorisation, as an option for treating visual impairment caused by macular oedema after central or branch retinal vein occlusion in ...

Conbercept is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for Branch ...

601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for ...

snmail.org Objectives High levels of plasma homocysteine have been reported to be toxic to the vascular endothelium, thereby creating an environment of hypercoagulability and occlusion. Elevated ...